Try our beta test site

Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma

This study has been terminated.
(changes in available treatments for melanoma)
Sponsor:
Information provided by (Responsible Party):
Ryan Sullivan, M.D., Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT01754376
First received: December 16, 2012
Last updated: January 18, 2017
Last verified: January 2017
  Purpose

This research study is a Phase II clinical trial of an investigational combination of drugs (vemurafenib and aldesleukin) to learn whether the combination works in treating a specific cancer. While both vemurafenib and aldesleukin are approved by the FDA for the treatment of metastatic melanoma, the FDA has not yet approved the combination of vemurafenib and aldesleukin.

Researchers have found that a large number of melanoma cells have mutations in the BRAF gene. It has been shown that vemurafenib blocks the effects of these mutations in the BRAF gene, and, as a result, may help to prevent cancer growth.

Aldesleukin, also referred to as IL-2, is an immunotherapy drug administered via IV infusion that increases the growth of key cells within the immune system that are responsible for targeting cancer cells. Activating more of these key cells, called T-lymphocytes and natural-killer cells, leads to increased cancer cell death.

The BRAF gene is located on a larger pathway called the MAPK pathway. Studies have shown that when a BRAF inhibitor, like vemurafenib is used to block the MAPK pathway, melanocytes, or cancer cells express more proteins on their surfaces, making them easier for T-lymphocytes and natural killer cells to recognize and kill them. This suggests that combining BRAF-targeted therapy with aldesleukin, which activates more of these white blood cells, can lead to an increase in the death of cancer cells.

In this research study, the investigators are looking to see whether the combination of vemurafenib (a BRAF-inhibitor) combined with aldesleukin(an immunotherapy drug) work together to produce a better health outcome in people with metastatic melanoma.


Condition Intervention Phase
Melanoma
Drug: Aldesleukin
Drug: Vemurafenib
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: COMBAT 1: A Phase II Trial of Combined BRAF-Targeted Therapy and Immunotherapy for Melanoma

Resource links provided by NLM:


Further study details as provided by Massachusetts General Hospital:

Primary Outcome Measures:
  • Progression Free Survival [ Time Frame: 3 years ]
    To assess the efficacy (as measured by progression-free survival (PFS)) of patients with metastatic melanoma with V600E mutation treated with the combination of vemurafenib and aldesleukin. Progression free survival is defined as the time between the first dose of study drug and the first occurrence of progression of disease or death from any cause.


Secondary Outcome Measures:
  • Overall Response Rate [ Time Frame: 2 years ]
    To determine the overall response rate (as defined as the rate of objective response (Complete Response (CR) or Partial Response (PR)) lasting continuously for 12 or more months, as compared to control therapy, and beginning at any point within 12 months of initiating therapy) in patients treated with aldesleukin and vemurafenib. In this limited cohort, response rate was calculated as the proportion of patients with partial (PR) or complete response (CR) divided by the total number of patients treated.

  • Overall Survival [ Time Frame: 2 years ]
    To determine the overall survival in patients treated with aldesleukin and vemurafenib. Overall survival is defined as the time between the first administration of study drug and death due to any cause.

  • Number of Participants Experiencing Grade 3 (Severe) Adverse Events [ Time Frame: 2 years ]
    To determine the toxicity and safety of concurrent administration of aldesleukin and vemurafenib by assessing adverse events experienced by participants.

  • Average Percentage of Doses Received Per Participant [ Time Frame: Approximately 9 months from start of treatment ]
    To assess whether the number of doses of aldesleukin that can be safely administered is affected by the co-administration of vemurafenib

  • Ratio of CD8+ T Cells to Regulatory T Cells [ Time Frame: Up to 8 weeks from start of treatment ]
    Tumor samples were collected pre-treatment, after 1-2 weeks on vemurafenib alone and after administration of aldesleukin (high-dose interleukin 2, HD-IL2). Multi-parameter flow cytometry was performed to measure the frequency of regulatory T cells and of CD8+ T cells. The CD8/Treg ratio was calculated.


Enrollment: 6
Study Start Date: January 2013
Study Completion Date: March 2016
Primary Completion Date: February 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment Arm

Oral vemurafenib 960 milligrams twice a day plus intravenous aldesleukin 600,000 IU/kg every eight hours to tolerance (maximum 14 doses) over five days on days 15-19 of cycle 1 and on days 1-5 of cycle 2. (A cycle is 28 days)

The first course of treatment will consist of three 28-day cycles (12 weeks): 2 weeks of lead-in vemurafenib plus 3 weeks on IL-2 plus 7 weeks wait.

A second course may be given at the discretion of the investigator, if there is evidence of tumor stability or regression.

Drug: Aldesleukin
Intravenous therapy given every 8 hours for up to 14 doses per week.
Other Names:
  • Interleukin 2
  • IL-2
  • Proleukin
Drug: Vemurafenib
Tablets given twice daily.
Other Names:
  • Zelboraf
  • PLX4032
  • RG7204
  • RO5185426

Detailed Description:

Subjects will take oral vemurafenib twice a day for 2 weeks. Following this lead-in period, subjects will receive aldesleukin via IV infusion on Day 15 of the study. One course of aldesleukin is 12 weeks long; subjects will receive aldesleukin via IV infusion every 8 hours for the first five days. Subjects will be hospitalized for the 5 days that they are receiving aldesleukin.

Week 1 of aldesleukin will be days 15-19 (M-F) of the 12 week cycle. Following Week 1 of therapy, subjects will be discharged from the hospital and only take vemurafenib at home for the following week. Subjects will then come in for one more week of aldesleukin during days 29-33 of the 12 week cycle. This is referred to as Week 2 of aldesleukin.

Subjects will continue to take vemurafenib twice daily during the course of aldesleukin. Their cancer will be evaluated at screening and at Week 12 following the beginning of the first aldesleukin course with a CT scan. After the first cycle, tumors will be evaluated every 8 weeks for the first year, then every 12 weeks for years 2 and 3, every 6 months for year 5, and annually thereafter.

If scans show that the subject's cancer has improved after the first course of aldesleukin, subjects may be allowed to continue on to a second course. In the event of a second course of aldesleukin, subjects will remain on vemurafenib throughout the second course.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically confirmed metastatic or unresectable melanoma with V600E mutation
  • Measurable disease
  • May have received prior immunotherapy (excluding interleukin 2)
  • Life expectancy greater than 3 months
  • Recovered from effects of previous surgery and/or traumatic injury
  • Must agree to use effective contraception

Exclusion Criteria:

  • Pregnant or breastfeeding
  • Psychological, familial or other conditions that could hamper compliance with protocol
  • Receiving other study agents
  • History of carcinomatous meningitis
  • Known active brain metastases
  • Have received a BRAF inhibitor
  • Uncontrolled intercurrent illness
  • HIV positive on antiretroviral therapy
  • History of a different malignancy within past 5 years (except cervical cancer in situ or basal/squamous cell carcinoma of the skin)
  • Active hepatitis B or C
  • Have received allogenic bone marrow transplant or organ transplant
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01754376

Locations
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02113
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02215
Sponsors and Collaborators
Massachusetts General Hospital
Investigators
Principal Investigator: Ryan J Sullivan, MD MGH Cancer Center
  More Information

Responsible Party: Ryan Sullivan, M.D., Principal Investigator, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT01754376     History of Changes
Other Study ID Numbers: 12-343
Study First Received: December 16, 2012
Results First Received: January 18, 2017
Last Updated: January 18, 2017
Individual Participant Data  
Plan to Share IPD: Yes
Plan Description: All raw analytic data on tumor and blood samples will be shared, upon acceptance of manuscript.

Keywords provided by Massachusetts General Hospital:
Metastatic
Unresectable
V600E mutation

Additional relevant MeSH terms:
Melanoma
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Nevi and Melanomas
Aldesleukin
Interleukin-2
Antineoplastic Agents
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents

ClinicalTrials.gov processed this record on March 29, 2017